Fig. 6: SARS-CoV-2 Omicron variants evade VL6-57 antibodies by mutations at residues S371-S373-S375. | Nature Communications

Fig. 6: SARS-CoV-2 Omicron variants evade VL6-57 antibodies by mutations at residues S371-S373-S375.

From: Antibodies utilizing VL6-57 light chains target a convergent cryptic epitope on SARS-CoV-2 spike protein and potentially drive the genesis of Omicron variants

Fig. 6

a Substituted residues among SARS-CoV-2 variants are highlighted in red on the surface of SARS-CoV-2 RBD. Among the 26 substitutions, 18 are shared among SARS-related-CoVs and are labeled in red, the other 8 substitutions are labeled in orange. b Substituted residues among RBDs of SARS-related-CoVs are highlighted in red. Among the 72 substitutions, 18 are shared with SARS-CoV-2 variants and are labeled in red. Epitope of R1-26 on RBD is encircled by cyan outlines in a and b. c Binding of R1-26, H18, and S2A4 to a series of Omicron BA.1 RBD mutants carrying 1-3 rescue mutations at S371, S373, and S375. BLI binding kinetic parameters are summarized in Supplementary Table 4. d Comparison of the VL6-57 mAb epitope structures on WT and Omicron BA.1 (left) or BA.2 (right) RBDs. Superposition shows differences in amino-acid sidechain orientations and main chain backbone structures. Source data for a and b are provided as a Source Data file.

Back to article page